Use of Intravenous Immunoglobulin Therapy at Unconventional Doses in Refractory Fulminant Systemic Lupus Erythematosus

The use of human intravenous immunoglobulins (IVIg) in systemic lupus erythematosus (SLE) currently relies on evidence from small case series and is mainly regarded as an off-label strategy in cases that are refractory to conventional therapies or poorly controlled with high doses of corticosteroids...

Descripción completa

Detalles Bibliográficos
Autores principales: Binello, Nicolò, Cancelli, Cristina, Passalacqua, Stefano, De Vito, Francesco, Lombardi, Gianmarco, Gambaro, Giovanni, Manna, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SMC Media Srl 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346821/
https://www.ncbi.nlm.nih.gov/pubmed/30756066
http://dx.doi.org/10.12890/2018_000934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346821/
https://www.ncbi.nlm.nih.gov/pubmed/30756066
http://dx.doi.org/10.12890/2018_000934

Ejemplares similares